Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marjolein, de Bruijn"'
Autor:
Lisanne M. Roelofsen, Paula Voabil, Marjolein de Bruijn, Petra Herzig, Alfred Zippelius, Ton N. Schumacher, Daniela S. Thommen
Publikováno v:
STAR Protocols, Vol 4, Iss 2, Pp 102282- (2023)
Summary: The lack of suitable models currently hampers our understanding of how the tumor microenvironment responds to immunotherapy treatment. Here, we present a protocol for ex vivo culture of patient-derived tumor fragments (PDTFs). We describe th
Externí odkaz:
https://doaj.org/article/c2276a0502114ffd841cacb2749b9c77
Autor:
Mandy van Gulijk, Anneloes van Krimpen, Sjoerd Schetters, Mike Eterman, Marit van Elsas, Joanne Mankor, Larissa Klaase, Marjolein de Bruijn, Menno van Nimwegen, Tim van Tienhoven, Wilfred van Ijcken, Louis Boon, Johan van der Schoot, Martijn Verdoes, Ferenc Scheeren, Sjoerd H. van der Burg, Bart N. Lambrecht, Ralph Stadhouders, Floris Dammeijer, Joachim Aerts, Thorbald van Hall
Publikováno v:
Science immunology, 8(83):eabn6173. American Association for the Advancement of Science
Science Immunology, 8, 83
Science Immunology, 8
Science Immunology, 8, 83
Science Immunology, 8
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with cancer do not respond well. Furthermore, in patients for whom ICB is initially successful, this is often short-lived because of the developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d64fa80023eea85e97f07ed848b69f6b
https://pure.eur.nl/en/publications/8c4b4852-3abc-41e4-9336-d01624bb4421
https://pure.eur.nl/en/publications/8c4b4852-3abc-41e4-9336-d01624bb4421
Autor:
Riccardo Mezzadra, Marjolein de Bruijn, Lucas T Jae, Raquel Gomez-Eerland, Anja Duursma, Ferenc A Scheeren, Thijn R Brummelkamp, Ton N Schumacher
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212053 (2019)
Experimental and clinical observations have highlighted the role of cytotoxic T cells in human tumor control. However, the parameters that control tumor cell sensitivity to T cell attack remain incompletely understood. To identify modulators of tumor
Externí odkaz:
https://doaj.org/article/7635229cc987440c80b60faae31cd35d
Autor:
Simone Brokamp, Annegien Broeks, Christian U. Blank, Petra Herzig, Marlous van den Braber, Daniela S. Thommen, Alfred Zippelius, Marjolein de Bruijn, Joyce Sanders, Ton N. Schumacher, Lisanne M. Roelofsen, Koen J. Hartemink, John B. A. G. Haanen, Kim Monkhorst, Paula Voabil, Sanne H. Hendriks
Publikováno v:
Nature Medicine. 27:1250-1261
Inhibitors of the PD-1–PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c45c19b51a9c099f12311a77da46c458
https://doi.org/10.1038/s41591-021-01398-3
https://doi.org/10.1038/s41591-021-01398-3
Autor:
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, Paula Voabil, Marjolein de Bruijn, Simone Brokamp, Irene Reijers, Judith Versluis, Gahyathiri Nallan, Hannah Triscott, Elizabeth McDonald, Joshua Tay, Georgina V. Long, Christian U. Blank, Daniela S. Thommen, Michele W.L. Teng
Publikováno v:
Science Translational Medicine, 14(642). AMER ASSOC ADVANCEMENT SCIENCE
Neoadjuvant immunotherapy with anti-cytotoxic T lymphocyte–associated protein 4 (CTLA4) + anti–programmed cell death protein 1 (PD1) monoclonal antibodies has demonstrated remarkable pathological responses and relapse-free survival in ~80% of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6676795225993de96cda1c9757ccd80f
https://doi.org/10.1126/scitranslmed.abj9779
https://doi.org/10.1126/scitranslmed.abj9779
Autor:
Paula, Voabil, Marjolein, de Bruijn, Lisanne M, Roelofsen, Sanne H, Hendriks, Simone, Brokamp, Marlous, van den Braber, Annegien, Broeks, Joyce, Sanders, Petra, Herzig, Alfred, Zippelius, Christian U, Blank, Koen J, Hartemink, Kim, Monkhorst, John B A G, Haanen, Ton N, Schumacher, Daniela S, Thommen
Publikováno v:
Nature medicine. 27(7)
Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8094aee10c0eedb40999c71de5771837
https://pubmed.ncbi.nlm.nih.gov/34478641
https://pubmed.ncbi.nlm.nih.gov/34478641
Autor:
Thijn R. Brummelkamp, Raquel Gomez-Eerland, Marjolein de Bruijn, Lucas T. Jae, Anja Duursma, Ton N. Schumacher, Ferenc A. Scheeren, Riccardo Mezzadra
Publikováno v:
PLOS ONE
PLoS ONE, 14(2)
PLoS ONE
PLoS ONE, Vol 14, Iss 2, p e0212053 (2019)
PLoS ONE, 14(2)
PLoS ONE
PLoS ONE, Vol 14, Iss 2, p e0212053 (2019)
Experimental and clinical observations have highlighted the role of cytotoxic T cells in human tumor control. However, the parameters that control tumor cell sensitivity to T cell attack remain incompletely understood. To identify modulators of tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b369c7d02a5932a4952abb5615c16c33
https://hdl.handle.net/1887/121317
https://hdl.handle.net/1887/121317
Autor:
Kirsten D. Mertz, Alfred Zippelius, Petra Herzig, Daniela S. Thommen, Viktor H. Koelzer, John B. A. G. Haanen, Marjolein de Bruijn, Marlous van den Braber, Ton N. Schumacher, Kim Monkhorst, Paula Voabil, Karlijn Hummelink
Publikováno v:
Cancer Immunology Research. 7:B050-B050
Reinvigoration of tumor-specific T-cells by cancer immunotherapies, in particular PD-1/PD-L1 blocking agents, has greatly improved clinical outcome in multiple cancer types. Nevertheless, durable clinical benefit is currently limited to a small numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb62dd47fc1063e6b9b519786b0d479c
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b050
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b050
Autor:
Roel G J, Klein Wolterink, Alex, Kleinjan, Menno, van Nimwegen, Ingrid, Bergen, Marjolein, de Bruijn, Yelvi, Levani, Rudi W, Hendriks
Publikováno v:
European journal of immunology. 42(5)
Allergic asthma is characterized by chronic airway inflammation and hyperreactivity and is thought to be mediated by an adaptive T helper-2 (Th2) cell-type immune response. Here, we demonstrate that type 2 pulmonary innate lymphoid cells (ILC2s) sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe1869fb1aafd30c806442cceaa74884
https://pubmed.ncbi.nlm.nih.gov/22539283
https://pubmed.ncbi.nlm.nih.gov/22539283